Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Findings from Bristol-Myers Squibb Update Understanding of Antihyperlipidemic Agents (Crystal Packing Arrangement, Chain Conformation, and...

share with twitter share with LinkedIn share with facebook
share via e-mail
08/17/2017 | 08:04pm CEST

Findings from Bristol-Myers Squibb Update Understanding of Antihyperlipidemic Agents (Crystal Packing Arrangement, Chain Conformation, and Physicochemical Properties of Gemfibrozil Amine Salts)

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Drugs and Therapies - Antihyperlipidemic Agents are discussed in a new report. According to news reporting from Merseyside, United Kingdom, by NewsRx journalists, research stated, "Salt formation is used to optimize pharmaceutical properties for carboxylic acid drugs, but selection can often be empirical."

Financial support for this research came from Bristol-Myers Squibb (see also Drugs and Therapies - Antihyperlipidemic Agents).

The news correspondents obtained a quote from the research from Bristol-Myers Squibb, "An extended series of salts of the anti-hyperlipidaemia carboxylic acid drug gemfibrozil was prepared using a related series of amine counterions to gain a molecular insight into the impact of crystal packing arrangements on their physicochemical properties. With only a few exceptions, the salts had similar crystal packing motifs."

According to the news reporters, the research concluded: "Although there was no discernible relationship between melting point of the salt form and the aqueous solubility of the salt across the whole data set, there were trends within structurally related series of salts' relating increasing melting enthalpy with increasing molecular weight of the counterion."

For more information on this research see: Crystal Packing Arrangement, Chain Conformation, and Physicochemical Properties of Gemfibrozil Amine Salts. Crystal Growth & Design, 2017;17(7):3743-3750. Crystal Growth & Design can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Crystal Growth & Design - www.pubs.acs.org/journal/cgdefu)

Our news journalists report that additional information may be obtained by contacting P. Timmins, Bristol Myers Squibb, Drug Prod Sci & Technol, Moreton CH46 1QW, Merseyside, United Kingdom. Additional authors for this research include S.E. David, C.H. Schwalbe, K. Asare-Addo, B.K. Conway and M. Ramirez.

Keywords for this news article include: Merseyside, United Kingdom, Europe, Antihyperlipidemic Agents, Fibric Acid Derivatives, Drugs and Therapies, Gemfibrozil Therapy, Organic Chemicals, Carboxylic Acids, Pentanoic Acids, Pharmaceuticals, Clofibric Acid, Bristol-Myers Squibb.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
08/17 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Update Understanding o..
08/17 BRISTOL MYERS SQUIBB : Data from Bristol-Myers Squibb Co. Provide New Insights i..
08/17 BRAINSTORM CELL THERAPEUTICS : Supports Commitment to ALS Patient Community with..
08/17 BRISTOL MYERS SQUIBB : Patent Issued for ROR.Gamma. Modulators (USPTO 9725443)
08/17 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Co. Report Details ..
08/17 BRISTOL MYERS SQUIBB : Research from Bristol-Myers Squibb Co. Yields New Finding..
08/16 Urban Outfitters and Agilent climb; Bristol-Myers skids
08/16 WEDNESDAY’S PIPELINE MOVERS : Bristol-Myers Squibb Company (NYSE:BMY) and ..
08/16 BRISTOL MYERS SQUIBB : Announces Topline Results from CheckMate 214
08/15 BRISTOL MYERS SQUIBB : Announces Topline Results from CheckMate -214, a Phase 3 ..
More news
News from SeekingAlpha
08/18 New Orphan Drug designations in U.S.
08/17 EXELIXIS : Time To Reach The Top
08/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 17, 2017
08/16 Bristol-Myers Squibb Combination Treatment Not At The End Of The Crossroad
08/16 Opdivo's Renal Failure Boosts Exelixis - Or Does It?
Financials ($)
Sales 2017 20 493 M
EBIT 2017 5 558 M
Net income 2017 4 624 M
Debt 2017 362 M
Yield 2017 2,80%
P/E ratio 2017 20,37
P/E ratio 2018 18,61
EV / Sales 2017 4,53x
EV / Sales 2018 4,37x
Capitalization 92 525 M
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,7 $
Spread / Average Target 2,3%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%357 079
ROCHE HOLDING LTD.4.99%218 752
NOVARTIS8.84%218 545
PFIZER0.59%196 221